New Hope For Dementia Including Alzheimer’s Disease
Truebinding TB006
Truebinding TB006 is an investigational treatment, offering potential hope for individuals with Alzheimer’s disease and other forms of dementia. Early clinical results have shown a trend toward reversing cognitive decline.
57 Million
As of 2021, approximately 57 million people worldwide are living with dementia, and nearly 10 million new cases are diagnosed each year. Around 60–70% of those cases are attributed to Alzheimer’s disease (1).
What is Truebinding TB006?
TB006 is a humanized monoclonal antibody designed to target Galectin-3 (Gal-3). By inhibiting Gal-3, TB006 may prevent the formation and promote the dissolution of amyloid-beta (Aβ) oligomers and plaques—key pathological features of Alzheimer’s disease—potentially improving synaptic integrity and cognitive function.
Preclinical studies using a surrogate antibody (mTB001) in Alzheimer’s disease mouse models (e.g., APPSwe and 5xFAD) demonstrated significant reductions in Aβ plaques, improved hippocampal-dependent spatial memory, and other neurodegeneration biomarkers after just two weeks.
Expanded Access Program (EAP) — Compassionate Use
2023: The FDA approved an Expanded Access Program (EAP) for TB006 under an intermediate-size patient protocol—the only one of its kind approved that year.
The EAP was renewed in 2024 and again in April 2025, demonstrating continued regulatory support and confidence in TB006’s potential for treating dementia and Alzheimer’s disease.
Under the EAP, TB006 is available not only for Alzheimer’s but also for other dementias including vascular, frontotemporal, Lewy body, and mixed pathology types.
TB006 has shown restorative and anti-inflammatory effects, with a favorable tolerability profile based on clinical trial results.
Get Started with Truebinding TB006 today:
561-283-1166
